Screener
MoonLake Immunotherapeutics MLTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $54.52M+49.5% | $56.01M+38.8% | $60.64M+69.7% | $49.76M+110% | $36.46M+180% | ||
| $70.02M+47.5% | $65.22M+31.5% | $71.43M+65.7% | $60.7M+98.5% | $47.49M+140% | ||
| $622K+307% | $248K+505% | $115K+25.0% | $95K+20.3% | $153K+119% | ||
| -$69.71M-74.5% | -$62.43M-36.9% | -$69.73M-97.0% | -$55.22M-128% | -$39.94M-192% | ||
| -$69.18M-46.9% | -$64.47M-31.0% | -$70.69M-65.3% | -$59.96M-98.3% | -$47.11M-142% | ||
| -$70.02M-47.5% | -$65.22M-31.5% | -$71.43M-65.7% | -$60.7M-98.5% | -$47.49M-140% |
FAQ
- Is MoonLake Immunotherapeutics profitable?
- MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.
- What is MoonLake Immunotherapeutics's earnings per share?
- MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.
- Where does MoonLake Immunotherapeutics's income statement data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.